Pfizer asked US regulators on Tuesday to allow boosters of its COVID-19 vaccine for anyone over the age of 18, a step that comes amid concerns about the further spread of the coronavirus with travel and vacation gatherings.
Older Americans and other groups particularly vulnerable to the virus have had access to a third dose of the Pfizer and BioNTech vaccine since September, yet the Food and Drug Administration has said it would act quickly to expand boosters to younger ages. if warranted.
Pfizer is submitting the first results of a booster study on 10,000 people to argue that it is time to expand the booster campaign even further.
While all three vaccines used in the US continue to offer strong protection against severe COVID-19 illness and death, the effectiveness of the injections against milder infections may decrease over time.
The new Pfizer study concluded that a booster could restore protection against symptomatic infection to nearly 96%, even when the extra-contagious delta variant was increasing. Side effects were similar to those seen with the company’s first two shots.
A median of 11 months after their last Pfizer vaccination, trial participants received a third dose or a sham injection. The researchers tracked any infection that occurred at least a week later, and so far they have counted five cases of symptomatic COVID-19 among booster recipients compared to 109 cases among people who received sham injections Local 10 Post.
So far, only those 65 and older and those 18 and older who have underlying medical conditions are eligible for the booster, as are those 18 to 64 who are at increased risk due to work or institutional settings.
Article Original From Miami Diario